Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate NRV II, LLC. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone973-242-0005
Debt
Current Ratio6.42
Quick Ratio6.42
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book2.14
Profitability
Net Income$-12,610,000.00
Net MarginsN/A
Return on Assets-84.11%
Miscellaneous
Employees5
OptionableOptionable
Neurotrope (NASDAQ:NTRP) Frequently Asked Questions
What is Neurotrope's stock symbol?
Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."
How were Neurotrope's earnings last quarter?
Neurotrope Inc (NASDAQ:NTRP) announced its quarterly earnings data on Tuesday, October, 30th. The company reported ($0.40) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.05. View Neurotrope's Earnings History.
When is Neurotrope's next earnings date?
What price target have analysts set for NTRP?
2 Wall Street analysts have issued 1 year price objectives for Neurotrope's shares. Their predictions range from $15.00 to $16.00. On average, they expect Neurotrope's stock price to reach $15.50 in the next year. This suggests a possible upside of 285.6% from the stock's current price. View Analyst Price Targets for Neurotrope.
What is the consensus analysts' recommendation for Neurotrope?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurotrope.
What are Wall Street analysts saying about Neurotrope stock?
Here are some recent quotes from research analysts about Neurotrope stock:
- 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (8/17/2018)
- 2. Maxim Group analysts commented, "Neurotrope reported 2Q18 with a net loss of $2.1M and $11.8M in cash on the balance sheet." (8/13/2018)
Has Neurotrope been receiving favorable news coverage?
Media coverage about NTRP stock has trended positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neurotrope earned a news impact score of 2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the next several days.
Who are some of Neurotrope's key competitors?
Some companies that are related to Neurotrope include BELLUS Health (BLUSF), Cue Biopharma (CUE), Processa Pharmaceuticals (PCSA), Proteostasis Therapeutics (PTI), Corvus Pharmaceuticals (CRVS), Chembio Diagnostics (CEMI), Adamis Pharmaceuticals (ADMP), Menlo Therapeutics (MNLO), XOMA (XOMA), Avadel Pharmaceuticals (AVDL), Millendo Therapeutics (MLND), Sol Gel Technologies (SLGL), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), ASLAN PHARMACEU/ADR (ASLN) and Checkpoint Therapeutics (CKPT).
Who are Neurotrope's key executives?
Neurotrope's management team includes the folowing people:
- Dr. Charles S. Ryan, CEO & Director (Age 54)
- Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 76)
- Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 58)
- Mr. Jeffrey Benison, Director of Corp. Communications
- Mr. David R. Crockford, VP of Regulatory Affairs (Age 73)
How do I buy shares of Neurotrope?
Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurotrope's stock price today?
One share of NTRP stock can currently be purchased for approximately $4.02.
How big of a company is Neurotrope?
Neurotrope has a market capitalization of $31.80 million. Neurotrope employs 5 workers across the globe.
What is Neurotrope's official website?
How can I contact Neurotrope?
Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]
MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
